Stock DNA
Pharmaceuticals & Biotechnology
EUR 348 Million (Micro Cap)
17.00
NA
0.17%
1.12
54.25%
9.49
Revenue and Profits:
Net Sales:
33 Million
(Quarterly Results - Mar 2025)
Net Profit:
5 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
13.28%
0%
13.28%
6 Months
22.88%
0%
22.88%
1 Year
26.09%
0%
26.09%
2 Years
0.69%
0%
0.69%
3 Years
18.37%
0%
18.37%
4 Years
37.44%
0%
37.44%
5 Years
0%
0%
0.0%
PharmaSGP Holding SE for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
14.35%
EBIT Growth (5y)
8.13%
EBIT to Interest (avg)
10.08
Debt to EBITDA (avg)
1.44
Net Debt to Equity (avg)
1.00
Sales to Capital Employed (avg)
1.01
Tax Ratio
25.06%
Dividend Payout Ratio
3.04%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
111.99%
ROE (avg)
59.87%
Valuation key factors
Factor
Value
P/E Ratio
17
Industry P/E
Price to Book Value
9.49
EV to EBIT
13.54
EV to EBITDA
10.16
EV to Capital Employed
5.25
EV to Sales
3.15
PEG Ratio
1.86
Dividend Yield
0.17%
ROCE (Latest)
38.74%
ROE (Latest)
54.25%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ
Mar'25
Dec'24
Change(%)
Net Sales
33.50
30.30
10.56%
Operating Profit (PBDIT) excl Other Income
9.20
10.30
-10.68%
Interest
0.70
0.00
Exceptional Items
0.00
-0.20
100.00%
Consolidate Net Profit
4.70
5.50
-14.55%
Operating Profit Margin (Excl OI)
204.20%
262.60%
-5.84%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2025 is 10.56% vs 0.33% in Dec 2024
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2025 is -14.55% vs 1.85% in Dec 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
118.80
101.10
17.51%
Operating Profit (PBDIT) excl Other Income
37.20
34.10
9.09%
Interest
4.40
4.70
-6.38%
Exceptional Items
1.20
0.60
100.00%
Consolidate Net Profit
19.50
16.40
18.90%
Operating Profit Margin (Excl OI)
234.00%
245.20%
-1.12%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 17.51% vs 17.83% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 18.90% vs 36.67% in Dec 2023
About PharmaSGP Holding SE 
PharmaSGP Holding SE
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






